CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00049-07v1
14/10/1311    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, S. L.
Right arrow Articles by Michon, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, S. L.
Right arrow Articles by Michon, F.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, October 2007, p. 1311-1317, Vol. 14, No. 10
1071-412X/07/$08.00+0     doi:10.1128/CVI.00049-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Epitope Specificities of the Group Y and W-135 Polysaccharides of Neisseria meningitidis{triangledown}

Samuel L. Moore,1* Catherine Uitz,2 Chang-Chun Ling,3 David R. Bundle,3 Peter C. Fusco,1 and Francis Michon1*

Wellstat Vaccines, 9 West Watkins Mill Road, Gaithersburg, Maryland 20878,1 Emergent Biosolutions, 300 Professional Drive, Gaithersburg, Maryland 20879,2 Alberta Ingenuity Centre for Carbohydrate Science, Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada3

Received 24 January 2007/ Returned for modification 27 April 2007/ Accepted 22 August 2007


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Previous studies have identified the length dependency of several polysaccharide (PS) protective epitopes. We have investigated whether meningococcal polysaccharides Y and W-135 possess such epitopes. Oligosaccharides (OSs) consisting of one or more disaccharide repeating units (RU) were derived from the capsular PSs of group Y and W-135 meningococci (GYMP and GWMP, respectively) by mild acid hydrolysis. The relative affinities of anticapsular antibodies binding to derivative OSs of different chain lengths were measured in inhibition enzyme-linked immunosorbent assays. As OS size increased from two to three RU, there was a notable increase in binding inhibition of rabbit anti-group Y antiserum. This pattern of antibody binding inhibition was also observed for rabbit antiserum to group W-135, though the inhibition increase was much more pronounced. In the cases of both OS species, the concentration of inhibiting antigen required to achieve 50% inhibition of rabbit immunoglobulin binding increased progressively as the inhibiting disaccharide chain length increased from 1 RU through greater than 50 RU. These data suggest that antibodies directed against both of these meningococcal PSs recognize conformational epitopes only fully expressed in higher-molecular-weight forms of these antigens.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Meningococcal disease, caused by Neisseria meningitidis, occurs mainly as either septicemia or meningitis, and is a worldwide health problem (23). The main virulence factor of N. meningitidis is its capsular polysaccharide (CPS), which protects it against complement-mediated bactericidal activity and opsonization (11, 17). Immunity to infection with many encapsulated bacteria is conferred by antibodies to the CPS (7, 18, 26).

N. meningitidis strains have been classified into at least 13 serogroups on the basis of the immune specificity of the PS capsule (25). Invasive infections are most frequently caused by five of these serogroups—A, B, C, Y, and W-135 (2). The proportion of meningococcal cases in the United States caused by serogroup Y has increased dramatically from 2% during 1989 to 1991 to 37% during 1997 to 2002 (2). Serogroup W-135, spread in association with the Hajj pilgrimage, has caused outbreaks and isolated cases in many countries, including the United States (4, 21). Of all cases of meningococcal disease in the United States among persons older than 11 years of age, 75% are caused by serogroup C, Y, or W-135 (2).

The CPSs are made up of either monosaccharides making a homopolymer, or from repeating units (RU) normally consisting of two to six sugar residues (30). CPSs vary significantly in their ability to stimulate specific antibody. As a very general rule, PSs with a molecular mass of >90,000 kDa are good immunogens in adults, while those with a molecular mass of <50,000 kDa are poorly immunogenic (8, 15, 20, 28). Coupling a PS or component oligosaccharide (OS) to a carrier protein to produce a conjugate molecule may result in immunogenic properties more like those of thymus-dependent antigens, including stimulation of higher levels of immunoglobulin G antibodies, enhanced memory responses, and immunogenicity in infants.

The biochemical basis of immunogenicity to bacterial CPS has been extensively studied. Immunity following meningococcal infection is serogroup specific (33). Susceptibility to systemic disease is linked to an absence of detectable bactericidal antibodies (7). Antibody responses can be greatly affected by their physicochemical properties: e.g., molecular size, specific determinants, and conformation (19). Both the group Y meningococcal polysaccharide (GYMP) and group W-135 meningococcal polysaccharide (GWMP) are highly immunogenic and are currently used as components of a vaccine against meningococcal meningitis in humans (10, 16). In addition, a conjugate vaccine containing these serogroups is now available (2).

Antibacterial PS-specific antibodies are generally of low intrinsic affinity (9). Enhancement of antibody binding can be observed if the target antigen has a repetitive structure, making those polymers functionally multivalent (9). Evidence for length-dependent conformational epitopes had previously been reported for group B streptococcus type III (3, 31, 34), group B N. meningitidis (13), Streptococcus pneumoniae type 14 (32), and Haemophilus influenzae type b (24) polysaccharides. It had been considered, in fact, that the recognition of conformational epitopes may be a more general phenomenon than previously appreciated in the interaction of anti-PS antibodies with bacterial CPS antigens (32). It has been speculated that more stable conformational epitopes of PS species can result from the restriction of rotational movement of individual sugar residues and that these conformations may be preferred by antibodies (24).

In this study, we examined the nature of the group-specific epitopes present on GYMP and GWMP. Both of these PSs contain sialic acid. Interaction of sialic acid with the PS backbone had previously been shown to be important in defining the conformational epitope of group B Streptococcus polysaccharide III (3).

(Portions of this work were presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 14 to 17 September 2003.)


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Growth of group Y and W-135 meningococcal strains. Meningococcal Slaterus Y strain and meningococcal W-135 S4383 strain were provided by Carl Frasch (CBER/FDA, Bethesda, MD). The strains were grown in shake flasks under agitation at 37°C in a modified Franz medium containing glucose and yeast extract. Cultures were harvested by centrifugation at 8,000 rpm, and supernatants were collected and filtered through 0.22-µm-pore filter units. The native Slaterus Y PS is 93% O acetylated (6). The W-135 strain expressed PS lacking O-acetyl groups as shown by 1H nuclear magnetic resonance (1H-NMR) on the purified PS.

Preparation of GYMPs and GWMPs. Microfiltered culture supernatants were concentrated by ultrafiltration using a filter device with a Biomax 300-kDa Pellicon membrane (0.5 m2) (Millipore Corp., Bedford, MA). The concentrated retentate was diafiltered 12 times against 1 M NaCl and then 10 times against deionized water and freeze-dried. The GYMP was then treated with mild base (0.1 N NaOH) at room temperature overnight and further purified by ultrafiltration to yield the de-O-acetylated high-molecular-weight form of the PS.

The high-molecular-weight purified "native" PSs were analyzed by gas chromatography-mass spectrometry with an Agilent 6890 gas chromatograph/5973 mass selective detector with a 30-m HP capillary column for sugar composition and by 1H-NMR spectroscopy at 500 MHz using a Bruker AMX-500 spectrometer. The sizes and polydispersity of the PS were determined using size exclusion chromatography (SEC) on line with the multiangle laser light-scattering (MALLS) detector (miniDawn; Wyatt Technology) (5).

Molecular modeling of group Y and W polysaccharides. Molecular modeling was carried out using the GEGOP (GEometry of GlycOProteins) program. GEGOP utilizes the modified HSEA (Hard Sphere Exo-Anomeric) force field in combination with Metropolis Monte Carlo calculations (27). Typically, the global minimum of each individual glycosidic linkage was calculated and the PS was constructed using the dihedral angles that correspond to the global minimum. If the PS chain could not be extended due to collision between the head and tail of the chain, the next local minimum was used to construct the PS chain. The PS (up to 10 RU) was finally minimized.

Preparation of PS-HSA conjugates. The human serum albumin (HSA; Sigma, St. Louis, MO) conjugates used for enzyme-linked immunosorbant assays (ELISAs) were prepared by reductive amination using either GYMP or GWMP. Each oxidized fragment of ~10 kDa was added to HSA followed by reduction with NaBH3CN as previously described (12).

Generation of OS inhibitors of discrete lengths. The GYMP was partially hydrolyzed with 0.1 N sodium acetate buffer (pH 3.0) at 80°C over a 2-h time frame. The OSs produced by mild acid hydrolysis have sialic acid as a terminal reducing sugar. The generated OSs of discrete length were then separated by SEC on a Superdex G-30 column (Pharmacia). The elution of the oligosaccharides was monitored by UV detection at 214 nm. Fractions containing each OS of a discrete length were combined and lyophilized. The purity and size of each of the OS inhibitors were determined by 1H-NMR spectroscopy at 500 MHz on a Bruker Instruments AMX 500 spectrometer (Billerica, MA). The same protocol was followed to generate GWMP OSs of discrete lengths. The 1H-NMR data were used to prove the presence of NeuAc at the reducing end of both the GYMP and GWMP OSs, as well as measuring their degree of polymerization (1).

Antisera. Reference typing rabbit antisera specific for GYMP, GWMP, group B meningococcal polysaccharide (GBMP), and group C meningococcal polysaccharide (GCMP) were obtained from DIFCO (Becton Dickinson, Franklin Lakes, NJ).

ELISAs for binding of antibody and inhibition of antibody binding. ELISAs for binding and inhibition of binding of rabbit antisera to microtiter plates coated with either GYMP-HSA or GWMP-HSA conjugates were performed as described previously (22).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Structures of GYMPs and GWMPs. The repeating disaccharide subunit structures of the GYMPs and GWMPs are shown in Fig. 1a. The GYMP is a repeating ->6)-{alpha}-D-Glc(1->4)-{alpha}-D-NeuAc(2-> disaccharide, while the GWMP is a repeating ->6)-{alpha}-D-Gal(1->4)-{alpha}-D-NeuAc(2-> disaccharide. A cursory examination of the nearly identical primary sequence and linkage positions of the GYMP and GWMP suggests that the two PSs will adopt nearly identical three-dimensional topologies, with the exception of the surface about carbon 4 of the hexose sugar, where the only structural difference exists between the two polymers. In the Y PS, the hydroxyl group at C4 is oriented in an equatorial position ("-eq" in H3eq/ax), while in W-135 antigen, this hydroxyl group is axial ("-ax" in "H3eq/ax"). It would be anticipated that surfaces composed of the sialic acid residue and parts of the hexose residue would be nearly identical. Modeling supports these expectations.


Figure 1
View larger version (50K):
[in this window]
[in a new window]

  		FIG. 1. (a) Structures of meningococcal polysaccharides. (b) Space-filling model of Neisseria meningitidis group Y polysaccharide structure. Green arrows indicate hydrophobic surfaces; blue arrows indicate hydrophilic surfaces. (c) Space-filling model of Neisseria meningitidis group W-135 polysaccharide structure. Green arrows indicate hydrophobic surfaces; red arrows indicate hydrophilic surfaces.

 
GYMP has a helical structure in the lowest energy conformation with four residues making one full turn. This arrangement creates identical surfaces on opposite sides of the molecule. Alternating RU make up these opposite surfaces. Figure 1b shows a space-filling model of the group Y PS structure. There is a hydrophobic surface (green arrow) on the lower left side and the upper right side (cannot be seen in this view) of the model. On the top and the bottom sides is the hydrophilic surface (blue arrows). For the group Y antigen, the O-4 atom of Glc disrupts the hydrophobic surface that is seen in group W-135 antigen (Fig. 1c). This is the largest structural difference between the two PSs that occurs on exposed surfaces, but the hydrophilic grooves are also different. GWMP has a related helical structure in the lowest energy conformation, with four residues making one full turn. Alternating RU make up these opposite surfaces. Figure 1c displays a model of the structure of the GWMP. Like the GYMP, there is a hydrophobic surface (green arrow) on the left side and the right side (which cannot be seen in this figure) of the model. On the top and the bottom sides is the hydrophilic surface (shown by red arrows).

In both Fig. 1b and c, the similarities of surfaces that involve the NeuAc acetamido and the exocylic carbon chain C7-C9 are nearly identical in their topologies. In the absence of immunological properties that might direct the immune response away from recognition of the sialic acid residues in each polysaccharide, it might be anticipated that sera induced by the two antigens would include populations of antibody that are highly cross-reactive and another population directed toward the surface containing C-4 of the hexose residue that would be highly specific. However, in reality in the case of the cross-reacting specificities, this is not significant, as serogrouping antisera produced in rabbits are typically used without cross-adsorption with related serogroups of meningococci (29).

Specificity of rabbit antisera on GYMP-HSA- and GWMP-HSA-coated plates. The specificity of rabbit antisera to the coated conjugate antigens was examined. Because the structures of GYMP and GWMP are so similar, antibodies produced against one of these PSs might be expected to cross-react with the other. Rabbit antisera to groups B, C, Y, and W-135 were serially diluted on a microtiter plate coated with GYMP-HSA conjugate (Fig. 2a). The ELISA titration curves display the strong reactivity of the anti-group Y antiserum and no corresponding cross-reactivity to the coated solid phase with the anti-group B, C, and W-135 antisera. Similarly, the same four rabbit antisera were serially diluted on a microtiter plate coated with GWMP-HSA (Fig. 2b). There is strong reactivity displayed by the anti-group W-135 antiserum and no significant cross-reactivity from any of the other three serotyping antisera.


Figure 2
View larger version (6K):
[in this window]
[in a new window]

  		FIG. 2. (a) ELISA titration of rabbit antisera on GYMP-HSA-coated plate. (b) ELISA titration of rabbit antisera on GWMP-HSA-coated plate. •, anti-N. meningitidis group B; {circ}, anti-N. meningitidis group C; {blacktriangledown}, anti-N. meningitidis group W-135; {triangleup}, anti-N. meningitidis group Y. OD 450, optical density at 450 nm.

 
Characterization of the de-O-acetylated GYMP and GWMP OS inhibitors. The purity and size of each of the OS inhibitors were determined by high-resolution 1H-NMR spectroscopy and SEC.

The proton chemical shift ({delta}) assignments for some of the signals of the GYMP and GWMP OS repeating units are collected in Table 1 and Table 2, respectively. The resonances assigned correspond to anomeric protons (H1) of the Gal/Glc residues, the H3eq/ax, and the N-acetyl protons (NHCOCH3) of NeuAc residues of each of the RU shown in Fig. 1a. The assignments were made by comparison with published data (1, 14), and some of them were confirmed by use of two-dimensional proton-proton (correlation spectroscopy [COSY]) and proton-carbon (heteronuclear single-quantum correlation [HSQC]) correlation experiments (data not shown). These NMR data prove the presence of NeuAc at the reducing end of both the GYMP and GWMP oligosaccharides, thus validating the basis for the degree of polymerization estimation.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Proton chemical shift in NMR analysis for GYMP oligosaccharides

 

View this table:
[in this window]
[in a new window]

  		TABLE 2. Proton chemical shift in NMR analysis for GWMP oligosaccharides

 
Determinant specificity of the GYMP. Inhibition of binding of rabbit anti-group Y antiserum to GYMP-HSA-coated plates using OSs ranging from 1 to approximately 55 disaccharide RU of GYMP was examined (Fig. 3). High-molecular-weight GWMP, used as a related PS inhibitor, did not inhibit the binding of the rabbit anti-group Y antiserum. One group Y disaccharide RU was a very poor inhibitor of antibody binding to the solid phase, while the binding inhibition increased markedly with 2 RU. It is unclear whether 100% inhibition of antibody binding could be achieved using 2 RU. There was complete inhibition of antibody binding when the subunit size was 3 RU or greater. Progressively increasing the size of the oligosaccharide from 3 RU through an estimated 55 RU progressively increases the relative affinity of the inhibition curves.


Figure 3
View larger version (18K):
[in this window]
[in a new window]

  		FIG. 3. Inhibition ELISA of rabbit anti-N. meningitidis Y antiserum on GYMP-HSA-coated plate. The mean molecular weight of larger fragments (≥18 RU) was determined by SEC-MALLS.

 
Determinant specificity of the GWMP. Binding inhibition of rabbit anti-group W-135 antiserum to GWMP-HSA-coated microtiter plates using OSs ranging from 1 RU to an estimated 66 RU of GWMP was also examined (Fig. 4). As with the group Y oligosaccharide subunits, inhibitors of 1 and 2 RU of GWMP were very poor inhibitors. In this experiment, there was a more dramatic increase in binding inhibition going from the 2-RU inhibitor to the 3-RU inhibitor than there was in the similar inhibition study conducted with anti-group Y antiserum (Fig. 3). Increasing the size of the GWMP subunit inhibitors progressively increased the apparent affinity of the inhibition curves.


Figure 4
View larger version (16K):
[in this window]
[in a new window]

  		FIG. 4. Inhibition ELISA of rabbit anti-N. meningitidis W-135 antiserum on GWMP-HSA-coated plate. The mean molecular weight of larger fragments (≥12 RU) was determined by SEC-MALLS.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We hypothesize that the rudimentary antibody binding sites for the GYMP and GWMP consist of 5 to 6 sugar residues, or 2.5 to 3 RU. The sixth residue, the reducing sialic acid, would likely be in equilibrium between the alpha and beta conformations depending whether it was unbound or bound by antibody, respectively. The fact that small OSs (3 RU) completely inhibited antibody binding to the both GYMP and GWMP at high OS concentrations indicates that the same antibodies bound to the smaller fragments as the larger PS but bound with lower apparent affinities. These results suggest that antibodies to both GYMP and GWMP bound to epitopes that were stabilized by higher-molecular-weight forms of the PS. The conformations of those epitopes in the lower-molecular-weight forms of these PS were less favorable for antibody binding, resulting in the lower-affinity interactions. In addition, the density of the stabilized epitope would likely increase with increasing chain length.

It is possible that the bivalent nature of the antibody molecules could lead to an increase in apparent avidity through monogamous bivalency. This effect would likely be maximized at an antigen chain length that would accommodate bivalent antibody binding to the same OS chain—roughly 10 to 20 sugar residues, or 5 to 10 RU (31)—and would not be a factor in apparent avidity increases beyond that OS chain size. Our results, however, clearly demonstrated an increase in apparent antibody avidity beyond those minimal OS chain sizes, thereby lending credence to a conformational epitope model for both the GYMP and GWMP antigens.

Another possibility is that bivalent antibody molecules could be capable of cross-linking epitopes on different OS chains in the same reaction mixture, thereby leading to a further increase in the apparent avidity of the antibody-OS interactions. In this case, the total antibody inhibition would continue to increase in ever smaller increments (as observed) with increasing OS chain length, approaching a theoretical maximum that could only be achieved at complete bivalent antibody binding.

The increase in apparent avidity could also be due to clumping of antibodies, as a result of noncovalent association, which may or may not be physiologically significant. In addition, antibodies with binding site specificity for a small OS may functionally discriminate between simple haptens consisting of those OSs and a PS of multiple RU of the same OS (29). High-affinity immune recognition of the bacterial CPS, rather than smaller OS fragments, would lead to activation of immune effector mechanisms (31).

NMR analyses of the inhibitors indicated minor conformational changes up through 4 RU for both OS species. What were not seen by NMR were the contributions that bound antibody molecules might make to the larger OS fragments and the stability that bound antibody might lend to the tertiary PS structures.

In summary, the conformational epitope model was more apparent for GWMP than GYMP since there was over a 300-fold increase in antibody inhibition, as the size of GWMP inhibitor grew from 3 RU to approximately 66 RU, compared to only a 35-fold increase, from 3 RU to approximately 55 RU, in the GYMP ELISA inhibition. The mechanism for this increase in inhibition, however, is not entirely clear. It would appear that the antibody binding to an antigenic site on a PS facilitated subsequent binding of other immunoglobulin molecules to the same PS, suggesting that these antibodies recognized conformational epitopes that are only fully expressed in high-molecular-weight forms of both PSs, although bivalent interactions may provide a contribution at higher PS concentrations.


   ACKNOWLEDGMENTS
 
We thank Harold Jennings for careful review of the manuscript and Wenling Dong for technical expertise.

We also thank Baxter Healthcare Corporation and BioVeris Corporation for the early support of this work.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Vaccine Research, Wellstat Vaccines, 9 West Watkins Mill Rd., Gaithersburg, MD 20878. Phone: (301) 519-7079. Fax: (301) 519-7117. E-mail for S. L. Moore: smoore{at}wellstatdiagnostics.com. E-mail for F. Michon: fmichon{at}wellstatvaccines.com Back

{triangledown} Published ahead of print on 5 September 2007. Back


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bardotti, A., G. Averani, F. Berti, S. Berti, C. Galli, S. Giannini, B. Fabbri, D. Proietti, N. Ravenscroft, and S. Ricci. 2005. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135. Vaccine 23:1887-1899.[CrossRef][Medline]
  2. Bilukha, O. O., N. Rosenstein, and National Center for Infectious Diseases, Centers for Disease Control and Prevention. 2005. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices. Morb. Mortal. Wkly. Rep. Recomm. Rep. 54:1-21.
  3. Brisson, J. R., S. Uhrinova, R. J. Woods, M. van der Zwan, H. C. Jarrell, L. C. Paoletti, D. L. Kasper, and H. J. Jennings. 1997. NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives. Biochemistry 36:3278-3292.[CrossRef][Medline]
  4. Centers for Disease Control and Prevention. 2000. Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia—United States, 2000. Morb. Mortal. Wkly. Rep. 49:345-346.[Medline]
  5. D'Ambra, A., J. E. Baugher, P. E. Concannon, R. A. Pon, and F. Michon. 1997. Direct and indirect methods for molar-mass analysis of fragments of the capsular polysaccharide of Haemophilus influenzae type b. Anal. Biochem. 250:228-236.[CrossRef][Medline]
  6. Fusco, P. C., E. K. Farley, C.-H. Huang, S. Moore, and F. Michon. 2007. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin. Vaccine Immunol. 14:577-584.[Abstract/Free Full Text]
  7. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.[Abstract]
  8. Gotschlich, E. C., M. Rey, J. Etienne, W. R. Sanborn, R. Triau, and B. Cvjetanovic. 1972. The immunological responses observed in field studies in Africa with group A meningococcal vaccines. Prog. Immunobiol. Stand. 5:485-491.[Medline]
  9. Greenspan, N. S., W. J. Monafo, and J. M. Davie. 1987. Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies. J. Immunol. 138:285-292.[Abstract]
  10. Griffiss, J. M., B. L. Brandt, and D. D. Broud. 1982. Human immune response to various doses of Y and W135 meningococcal polysaccharide vaccines. Infect. Immun. 37:205-208.[Abstract/Free Full Text]
  11. Hoang, L. M., E. Thomas, S. Tyler, A. J. Pollard, G. Stephens, L. Gustafson, A. McNabb, I. Pocock, R. Tsang, and R. Tan. 2005. Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin. Infect. Dis. 40:e38-e42.[CrossRef][Medline]
  12. Jennings, H. J., A. Gamian, F. Michon, and F. E. Ashton. 1989. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1. J. Immunol. 142:3585-3591.[Abstract]
  13. Jennings, H. J., R. Roy, and F. Michon. 1985. Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. J. Immunol. 134:2651-2657.[Abstract]
  14. Jones, C., and X. Lemercinier. 2002. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J. Pharm. Biomed. Anal. 30:1233-1247.[CrossRef][Medline]
  15. Kabat, E. A., and A. E. Bezer. 1958. The effect of variation in molecular weight on the antigenicity of dextran in man. Arch. Biochem. Biophys. 78:306-318.[CrossRef][Medline]
  16. King, W. J., N. E. MacDonald, G. Wells, J. Huang, U. Allen, F. Chan, W. Ferris, F. Diaz-Mitoma, and F. Ashton. 1996. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J. Pediatr. 128:196-202.[CrossRef][Medline]
  17. Klein, N. J., C. A. Ison, M. Peakman, M. Levin, S. Hammerschmidt, M. Frosch, and R. S. Heyderman. 1996. The influence of capsulation and lipooligosaccharide structure on neutrophil adhesion molecule expression and endothelial injury by Neisseria meningitidis. J. Infect. Dis. 173:172-179.[Medline]
  18. Lancefield, R. C., M. McCarty, and W. N. Everly. 1975. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J. Exp. Med. 142:165-179.[Abstract/Free Full Text]
  19. Lee, C. J. 1987. Bacterial capsular polysaccharides—biochemistry, immunity and vaccine. Mol. Immunol. 24:1005-1019.[CrossRef][Medline]
  20. Lindberg, A. A., L. T. Rosenberg, A. Ljunggren, P. J. Garegg, S. Svensson, and N.-H. Wallin. 1974. Effect of synthetic disaccharide-protein conjugate as an immunogen in Salmonella infection in mice. Infect. Immun. 10:541-545.[Abstract/Free Full Text]
  21. Lingappa, J. R., A. M. Al-Rabeah, R. Hajjeh, T. Mustafa, A. Fatani, T. Al-Bassam, A. Badukhan, A. Turkistani, S. Makki, N. Al-Hamdan, M. Al-Jeffri, Y. Al Mazrou, B. A. Perkins, T. Popovic, L. W. Mayer, and N. E. Rosenstein. 2003. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg. Infect. Dis. 9:665-671.[Medline]
  22. Michon, F., S. L. Moore, J. Kim, M. S. Blake, F.-I. Auzanneau, B. D. Johnston, M. A. Johnson, and B. M. Pinto. 2005. Doubly branched hexasaccharide epitope on the cell wall polysaccharide of group A streptococci recognized by human and rabbit antisera. Infect. Immun. 73:6383-6389.[Abstract/Free Full Text]
  23. Peltola, H. 1983. Meningococcal disease: still with us. Rev. Infect. Dis. 5:71-91.[Medline]
  24. Pillai, S., S. Ciciriello, M. Koster, and R. Eby. 1991. Distinct pattern of antibody reactivity with oligomeric or polymeric forms of the capsular polysaccharide of Haemophilus influenzae type b. Infect. Immun. 59:4371-4376.[Abstract/Free Full Text]
  25. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.[Free Full Text]
  26. Schneerson, R., L. P. Rodrigues, J. C. Parke Jr., and J. B. Robbins. 1971. Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b. J. Immunol. 107:1081-1089.[Abstract/Free Full Text]
  27. Stuike-Prill, R., and B. Meyer. 1990. A new force-field program for the calculation of glycopeptides and its application to a heptacosapeptide-decasaccharide of immunoglobulin G1. Importance of 1-6-glycosidic linkages in carbohydrate peptide interactions. Eur. J. Biochem. 194:903-919.[Medline]
  28. Szu, S. C., X. R. Li, R. Schneerson, J. H. Vickers, D. Bryla, and J. B. Robbins. 1989. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect. Immun. 57:3823-3827.[Abstract/Free Full Text]
  29. Tsang, R. S. W., and W. D. Zollinger. 2005. Serological specificities of murine hybridoma monoclonal antibodies against Neisseria meningitidis serogroups B, C, Y, and W135 and evaluation of their usefulness as serogrouping reagents by indirect whole-cell enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 12:152-156.[CrossRef][Medline]
  30. Weintraub, A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr. Res. 338:2539-2547.[CrossRef][Medline]
  31. Wessels, M. R., A. Munoz, and D. L. Kasper. 1987. A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc. Natl. Acad. Sci. USA 84:9170-9174.[Abstract/Free Full Text]
  32. Wessels, M. R., and D. L. Kasper. 1989. Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide. J. Exp. Med. 169:2121-2131.[Abstract/Free Full Text]
  33. World Health Organization Working Group. 1995. Control of epidemic meningococcal disease: WHO practical guidelines. Fondation Marcel Mérieux, Lyon, France.
  34. Zou, W., R. Mackenzie, L. Thérien, T. Hirama, Q. Yang, M. A. Gidney, and H. J. Jennings. 1999. Conformational epitope of the type III group B Streptococcus capsular polysaccharide. J. Immunol. 163:820-825.[Abstract/Free Full Text]

Clinical and Vaccine Immunology, October 2007, p. 1311-1317, Vol. 14, No. 10
1071-412X/07/$08.00+0     doi:10.1128/CVI.00049-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00049-07v1
14/10/1311    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, S. L.
Right arrow Articles by Michon, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, S. L.
Right arrow Articles by Michon, F.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS